Logo

Novavax and Serum Institute of India Collaborate to Develop and Commercialize Vaccines for Malaria

Share this

Novavax and Serum Institute of India Collaborate to Develop and Commercialize Vaccines for Malaria

Shots:

  • Novavax to receive royalties on the sales of vaccines and will provide its Matrix-M vaccine adjuvant to SII. Additionally- the company gets right to commercialize SII-manufactured vaccine in high-income countries- primarily in the travelers and military vaccine markets
  • SII gets access to utilize Novavax’s Matrix-M vaccine adjuvant with its malaria vaccine candidate (R21 malaria vaccine)- licensed from the Jenner Institute at Oxford University in 2017
  • R21 malaria vaccine along with Matrix-M is currently being evaluated in P-IIb study to target Plasmodium falciparum-induced malaria with its expected results to be reported in Q2’20

Click here ­to­ read full press release/ article | Ref: Novavax  | Image: Fierce Pharma


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions